2021
3
2021-11-10 13:54:02
"Operator: Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma Third Quarter 2021 Earnings Conference Call. I would now like to turn the call over to George Grofik, SVP, Head of Investor Relations and Communications. Please go ahead, sir.
George Grofik: Thank you, Josh. Good morning, good afternoon to everyone on the call, and welcome to Royalty Pharma 's third quarter results conference call. You can find the slides to this call on the Investors page of our website at royaltypharma.com.  Moving to Slide 3, I would like to remind you that information presented in this call contain forward-looking statements that involve known and unknown risks, uncertainties, and other factors may cause actual results to differ materially. I refer you to our 10-K on file with the SEC for a description of these risk factors. And with that, please advance to Slide 4.   speakers on the call today are Pablo Legorreta, Founder and Chief Executive Officer, Jim Reddoch, EVP, Co-Head of Research and Investments and Chief Scientific Officer, Marshall Urist, EVP, Co-Head of Research and Investments, Terry Coyne, EVP, Chief Financial Officer, and Pablo will discuss the key highlights after which Jim and Marshall will provide an update on our Royalty portfolio and upcoming event.  Terry will then review the financials and after concluding remarks from Pablo, we will hold a Q&A session. Chris Hite, our Vice Chairman, will also join the Q&A. And with that, I'd like to turn the call over to Pablo.
Pablo Legorreta: Thank you, George, and welcome to everyone on the call. I am delighted to report another quarter of strong financial performance and strategic execution. We delivered double-digit top and bottom-line growth despite the end of the term for our HIV Royal. We maintain a robust and active deal pipeline. We expect to build on our strong year-to-date momentum with transactions announced so far of $2.8 billion.  We saw important progress in our development space portfolio with positive Phase III results for PT027 and asthma, and the breakthrough designation granted by FDA to gantenerumab in Alzheimer's. Lastly, based on the strong business dynamics, we're again raising our guidance for adjusted cash receipts for 2021.  On Slide 7, you can see our financials in a little more detail. In the third quarter, we delivered 24 % growth in adjusted cash receipts, our top line, and 12 % growth and adjusted cash flow, our bottom line. The strong momentum puts us in a tremendous position to deliver another year of strong financial performance in 2021, as Terry will speak too, when we -- when she discusses our raised guidance for the current year.  Slide 8 sets our track record of impressive growth since our IPO in June 2020. I am really proud of this slide as it underscores the power of our business model. As you can see in this graphic, we have reported 6 consecutive quarters above the double-digit bottom-line growth and very strong top line growth as well.  I mentioned earlier, the loss of our  royalties, which were our fourth largest source of royalties in 2020, accounting for 13 % of  royalty receive. We have digested this impact and still delivered around 20 % top and bottom-line growth in the first 9 months of 2021. This speaks to the strength and breadth of our existing portfolio and the momentum for our recent Royalty transactions.  It is also a part of what makes Royalty Pharma a unique investment in life sciences. Our impressive ability to grow through explorations and continuing to diversify the portfolio with value-enhancing Royalty acquisitions fully set s us apart from other biopharma companies. With that, I will hand over to Jim to update you on our Royalty portfolio.
Jim Reddoch: Thank you, Pablo, and hello, everyone. Today, Marshall and I want to spend a few minutes updating you on our development stage portfolio before highlighting some important upcoming events. Slide ten lays out the significant patient and commercial potential for PTO-27. This is AstraZeneca's investigational asthma therapy, for which Royalty Pharma has been co-funding clinical development through a billion since 2018.  We returned to the PTO27, as it is a potential first-in-class fixed dose combination of budesonide, an inhaled corticosteroid, and albuterol, a short-acting beta2-agonists. It targets both the symptoms and the underlying inflammation and asthma. We were therefore delighted last month AstraZeneca announced that the 2 pivotal Phase 3 trials of PT027, known as DENALI and MANDALA met all the primary endpoint.  AstraZeneca plans to release detailed data at an upcoming medical meeting, in a regulatory filing is expected in the first half of 2022. In return for our role in funding the clinical program, Royalty Pharma is entitled to receive royalties in the low single-digits in addition to success-based milestones.  Given the scale of the addressable market as well as the unmet need for novel rescue therapies and asthma, consensus estimates project that sales for PTO-27 will exceed $1 billion. This has the potential to become a meaningful new royalty stream for Royalty Pharma. On Slide 11, including PTO-27, our investment in development-stage therapies since 2012 is approximately $7.7 billion.  Over that period, we've been very successful in racking winners, especially when compared with industry benchmarks, with a 79 % approval rate by the number of investments and then 95% approval rate by the value of our investments. PT027 is another example of Royalty Pharma's ability, sometimes years before our potential commercial launch to identify opportunities of unmet need in therapeutic areas that are overlooked were considered well-served or genericized. In asthma, inhaler therapies for earlier stage patients are commonly viewed as a market segment that is satisfied by generic inhalers. However, PT027 as the novel combination inhaler that uniquely facilitates steroid delivery to suppress inflammation at times of increased asthma symptoms to prevent subsequent exacerbations.  Biotechs NURTEC is another example where the market was felt to be satisfied by existing drugs. However, the strong launch of the oral CGRP inhibitors, including NURTEC, has revealed significant unmet need among people suffering from migraine. And we look forward to identifying more opportunities like PT027 and NURTEC in the years to come. Our rigorous evaluation process is the primary reason for our high success rate.  We conduct extensive due diligence, both through our experienced research and investments team internally, but also through leading external experts to gain comfort on the science and the patient need. Our starting point that's always strong clinical benefit, where the need is large.  But we also benefit from being agnostic to therapy area so that we can choose from the most compelling opportunities available across the industry. And a few additional successes are highlighted on the slide, including Trodelvy and more recently, Evrysdi. And today we have a portfolio of 9 development stage therapies.  To close here,  builds on our track record of successful investment in development stage therapies and we will continue to pursue this important business stream of development-stage opportunities while maintaining an appropriate balance with royalties on improved medicines in order to optimize our overall risk-return profile. And I will now turn it over to Marshall to discuss upcoming events.
Marshall Urist: Thanks, Jim. And good morning. Slide 13 lays out the upcoming clinical and regulatory events for our portfolio over the next 12 months or so. For the balance of 2021, we expect Phase 2-3 results for intranasal gantenerumab in migraine. And looking to next year, 2022 is likely to be a very milestone reach here with a number of important Phase III readouts for our portfolio.  This includes Phase II results for Trodelvy in third line HR positive metastatic breast cancer, from Cabometyx in combination with Opdivo and Yervoy in first-line renal cell carcinoma, as well as in prostate and lung cancer. Tremfya in ulcerative colitis and Crohn's, gantenerumab, Alzheimer's, otilimab in rheumatoid arthritis and self-direct and depression.  Turning to regulatory actions, this quarter, we expect a European regulatory decision on Trodelvy in triple-negative breast cancer. In 2022, we expect a filing on PT027, as Jim mentioned earlier, and also European regulatory decision on  in migraine, where it will be marketed out of the brand name Vydura.  We're pleased to see the news of a partnership between Biohaven and Pfizer to market by Vydura outside of the U.S. Pfizer will be a strong partner to maximize the reach efficient new class of medicines around the world. In some, we expect to see a number of important milestones over the next year, if positive, many of these could add significantly to the long-term outlook for our adjusted cash flow.  Now before turning it over to Terry, I wanted to make a few final comments on our portfolio's Medicare exposure, given the proposed U.S. drug pricing Legislation Reform that was -- that has been receiving significant investor retention. While nothing has been finalized, our business in aggregate has minimal Medicare exposure across Part B and Part D.  And based on the draft language, we would expect only 1 or 2 products, Imbruvica and Xtandi to be in the top drugs by Medicare spending. And as a reminder, Xtandi's Royalty duration is through 2027 to 2028. From what we have seen in the proposed legislation, our initial view is that we would anticipate only a very small headwind to our business without considering any increase in volume from potentially improved patient access.  But more importantly, this potential change to the U.S. drug pricing legislation highlights some strengths of our business model and strategy. First, the fact that we're continually adding new product royalties to our portfolio means that we're uniquely positioned to rapidly react to any changes to the reimbursement environment in our forecast and valuations.  Second, our therapeutic area, agnostic business model means that the full span of biopharma innovation is open to us without the constraints of legacy therapeutic area R&D, or commercial infrastructure. Of course, we'll continue to monitor the developments in Washington and respond appropriately. And with that, I'll hand it over to Terry.
Terry Coyne: Thanks, Marshall. Let's move to Slide 15. Total royalty receipts grew 21 % versus the year-ago period. Growth drivers in the quarter included our largest franchise, cystic fibrosis, as well as Tysabri payments from Biohaven, new royalties, and a 1-time milestone payment of $45 million related to Sanofi's diabetes therapy Soliqua.  These positive factors more than offset the decline in royalty receipts from our legacy HIV franchise. As mentioned on last quarter's call, the Soliqua milestone we received this quarter was previously expected in 2022. For your modeling consideration, we would therefore expect the other product's royalty receipts line in 2022 to be between $200 million to $250 million. Slide 16 shows how our royalty receipts translated to strong adjusted cash flow in the third quarter.  As you're aware, adjusted cash receipts is a key non-GAAP metric for us, which we arrive at after deducting non-controlling interest. This amounted to $587 million in the quarter, growth of 24 % compared with last year's third quarter, as Pablo noted earlier, when we move left to right, operating and professional costs of $54 million equated to 9.1% of adjusted cash receipts, consistent with the revised full-year guidance I will speak to momentarily.  R&D funding remained at a low level. The major step-up in net interest is $65 million reflected the semiannual interest payment associated with our $6 billion unsecured note offering in 2020. As a reminder, these payments are paid in the first and third quarters. The other line was $27 million, which largely -- which was largely attributable to a $60 million one-time cash payment related to our bond offering in July.  Adjusted cash flow, our bottom-line earnings, was $441 million or $0.73 per share. This translates to an adjusted cash flow margin of 75.2%. Given that the quarter included the semi-annual interest payment, which was equivalent to around 11 % of adjusted cash receipts, and the one-time bond payment. This margin underscores the strong cash conversion in our business model.  On slide 17, we continue to maintain our financial firepower despite the $2.3 billion of capital deployed on royalty acquisitions year-to-date. At the end of September, we had $2 billion of cash in marketable securities, similar to our position at the end of 2020. Major cash inflows over the 9 months included adjusted cash flow of $1.3 billion plus the $1.3 billion of net proceeds from our innovative debt financing in July.  As a reminder, this bond issuance included a $600 million social bond which reflects our commitment to ESG and corporate social responsibility, which we discussed on last quarter's call. These combined inflows of $2.6 billion were broadly offset by the capital we deployed on royalty acquisition and the dividends and distributions.  Hence, the limited change over the period on a net basis. We currently have $7.3 billion of investment-grade debt, with leverage of 2.7 times EBITDA on a net basis and 3.76 times EBITDA on a total basis, and a weighted average debt coupon of 2.24% to 4 %. Our $1.5 billion revolving credit facility is untapped, which in addition to cash-on-hand gives us a strong liquidity position, making us very well-positioned to execute on our business plan.  My final slide sets out our raised full-year 2021 guidance. We now expect adjusted cash receipts to be in the range of $2.11 billion to $2.13 billion an increase of approximately $20 million at the midpoint of our previous guidance. The increase in our guidance is driven by strong underlying performance of our portfolio. Our new adjusted cash receipt guidance represents growth of between 17 % and 18 % over the $1.8 billion we delivered in 2020.  Turning to operating costs, we now expect these to be approximately 9 % of adjusted cash receipts, which is at the low end of our previous guidance for between 9 % and 10 %. This guidance implies a step-up in costs at this line in the fourth quarter due to the timing of various expenses.  Net interest paid for the year is still expected to be around a $130 million, but you should note, we expect net interest paid in 2022 to increase to around a $170 million following the bond offering in July that I just discussed. In line with our established practice, this guidance is based on our portfolio as of today and does not take into account any future acquisitions. With that, I'd like to hand the call back to Pablo for his closing comments.
Pablo Legorreta: Thanks, Terry. Let me close by first reiterating how delighted I am with how our business has progress in 2021. And by secondly, inviting you to our  Investor Day in the spring of 2022. We're very excited by the opportunity to engage with investor to lay out why, we're so excited about the future growth prospects for the business.  We plan to include additional discussion of the outlook for Royalty funding in life sciences innovation, our updated capital deployment objective, and long-term growth targets. And of course, you will have plenty of opportunity to ask questions and interact with management. We very much hope that we can hold our Investor Day in-person, but we will, of course, be guided by the pandemic backdrop, as we want all participants to feel comfortable and, above all, safe. Whether in person or virtual I am confident we will have a compelling presentation and I hope as many of you as possible, we'll be able to join us on the date. We'll follow up with additional details and a specific date as we're closer to the event. With that, I would like to open the call for questions. Back to you, George.
George Grofik: Thank you, Pablo. And Josh will now open up the call to your questions. If you could please take the first question.
Operator: Thank you.  Our first question comes from Chris Schott with J.P. Morgan. You may proceed with your question
Chris Schott: Oh, great. Thanks so much for the questions. I guess my first question was for Pablo or Terry. CF has obviously emerged as a controversy in the story, and I -- you've talked about the ability to significantly diversify your business away from any potential risks that may emerge here over the next kind of 5 or 10 years.  Can you elaborate a bit more in the framework that you're thinking about how quickly the Company can diversify its business and go about your capital deployment rates, etc. And maybe as part of that, I think you've talked about every billion dollars of capital deployed translating to about a $170 million of adjusted cash receipts 5 years later. I think that was based on deals over the past few years.  Is that a decent lens to think about as we think about how quickly capital deployment could translate to adjusted cash receipts going forward, or the type of deals that you're looking at now having either different payoff timelines or just different profiles than what we've been thinking about in the past. Thanks so much.
Pablo Legorreta: Chris, thanks for your question and let me make some initial remarks and Terry can take over so I can be a bit more specific about cystic fibrosis. So, I think the calculation we made about a $170 million of cash receipts 5-years out per billion is actually pretty reasonable. We've looked at many periods and the amount of capital invested over different periods of time.  And there is a range, but I think it's a fairly reasonable and also conservative number that you could use to model out what would -- what happens with our capital deployment. The other comment to make is that we actually have been doing really well when you look at investments every year, every quarter, and capital deployed.  And as you have seen by following us, we had initially guided up to $1.5 billion of capital deployed per year, about $7 billion over 5 years after our IPO. And if you just look at the last 3 years capital deployed $2.3 billion in 2019, $2.4 billion in 2020, which was the year of our IPO last year.  And this year so far, we're at $2.8 billion, so we're obviously exceeding in a meaningful way the billion-and-a-half of capital deployed, we're obviously in excess of $2 billion per year, and this year, $2.8 billion. So, we're very excited about the way the business has progressed. We're now very close to -- I mean, we're over $5 billion of capital deployed. Of course, that $7 billion goal and $5 billion deployed in a matter of sort of 18 months or so. So, I think -- and we also have a Terry, very broad, rich, exciting pipeline ahead of us. And just the tailwinds that exist in this industry are so strong that I think we feel very confident of delivering on our guidance and expectations that investor had. I think it is just going to happen.  There's no question that deploying this amount of capital per year is going to make the reliance on our cystic fibrosis royalties much lower -- much, much lower than what it is now. And that's going to happen fairly quickly if you just look out in 3 years, 5 years, it's going to start to diminish.  And we're adding up really exciting product with very interesting growth dynamics and really top tier products marketed by some of the strongest companies in life sciences. There were some indications with very high quality, very exciting product. But, Terry, why don't you add some additional comments about CF?
Terry Coyne: Yeah, sure. Thanks for such a good question. I think -- 1st off, we saw the data that was disclosed by Vertex a few months ago, and we think it's difficult to draw too many conclusions on a Phase 2 study with relatively low patient numbers where the full data hasn't been presented. But based on the top-line data, there is nothing we saw that suggest the efficacy of Vertex 's new triple is superior to Trikafta.  We also believe that deuterated Kalydeco is simply Kalydeco and it should be royalty-bearing at the same rate as Kalydeco. If that's the case, are Royalty on the new Vertex triple where the deuterated Kalydeco and Tezacaftor components are royalty-bearing will be 8 % and this isn't much different than our Royalty on Trikafta, which is a little over 9 %.  But hypothetically speaking, even if deuterated Kalydeco is not royalty-bearing, and only the Tezacaftor portion is royalty-bearing, our Royalty on the new Vertex triple will be 4 %. We continue to believe that even if a new triple is approved, Trikafta will play a significant role in the treatment of CF over the long term, given the impressive long-term safety and efficacy it's achieved.  Remember, many CF patients take 30 to 50 pills per day for their disease, so it's not clear how important the potential once-daily option will really be without a material improvement in efficacy, especially when considering the long experience patients will have with Trikafta. That being said, we recognize that there's potential for Vertex 's new triple to capture share of the market in the back half of the decade, and we appreciate that investors want to understand the risk to our adjusted cash receipts under downside scenarios.  So, we estimate that if the new Vertex triple is approved in only the Tezacaftor component of the new triples Royalty bearing, our adjusted cash receipts towards the end of the decade could be reduced by a couple $100 million versus -- per year versus what they would have been if all components to the new triple were royalty-bearing. So, to put this into context, our adjusted cash receipt this year are estimated to be in the range of 2.11 to 2.13 billion.  And as Pablo just mentioned, we're investing billions of dollars per year, adding dozens of products to the portfolio every 5 years, many of which will be blockbusters. We have products that face loss of exclusivity or lose market share to competitors every year. And this is actually I think a great example.  This year, our HIV Royalty expired and our adjusted cash received from HIV are expected to decline by nearly a $150 million in 2021, and we're still expected to grow total adjusted cash receipts by 18 % at the midpoint of our guidance. This really highlights the resilience of our business model, and we continue to believe that Royalty Pharma is uniquely positioned to overcome these risks.
Pablo Legorreta: Chris, I think the comments Terry made were excellent, and important for investors to really understand well. And then think of things like a potential loss of a person, HIV, $150 million  of revenue, and with how strong the performance has been this year, sailing through that expiration and still delivering high double-digit growth in our business.  And this is something that I've seen over and over again over 2 decades. We lost our reflects on patents, no issue. And we lost many other patents, HUMIRA, which was a big one and we just sailed through that. So, I think the business has this incredible resilience that's very unique, that few businesses have in life sciences combined with very, very strong, predictable growth. And I'll stop there.
Chris Schott: Great. Thanks so much for the color.
Operator: Thank you. Our next question comes from Andrew Baum with Citi. You may proceed with your question.
Andrew Baum: Thank you. A couple of questions. Firstly, you commented on Vertex 's new triple. Perhaps you could comment on any thoughts you have on the API's portfolio, I take the posted data problematic, but it will still be interesting. And then, second, could you talk about whether you are seeing any increased competition, pushing out asset prices for some of the more attractive Royalty deals.  Maybe you could talk to MorphoSys. I know that Blackstone is building a presence in the area within  the product chiefs to compete. But more broadly, what are you saying? Is there any near - term risk, or it's just the opportunities available so broad that there's more than room for 1?
Pablo Legorreta: Yes. I'll ask Terry to again, comments on the Avi question but with regards to your question about competition, this is a topic that has been in people's minds, investorsâ€™ minds, again, for 2 decades. And when we were private, it was our private investors and now that we're public, it's our public investors. And what's been really great to see is how competition comes and goes and it's been of all times and flavors.  Many investors have joined or tried to enter the market ended up exiting, and there's been many of them. And I think there's obviously new competitors and strong competitors, but I think we have some incredibly unique attributes that make us very unique and very strong. The low cost of capital that we have with that that we are able to borrow at fixed rates of 2 %.  The ability of us to invest billions of dollars in unapproved products taking single-product risk of 300, 400, 500 million and not really being concerned with that because of the scale, the size of our portfolio, the fact that we generate $2 billion plus of revenue per year that's growing with a very strong 90 % EBITDA margin allows us to take risks where very few can.  And I would also just like to remind you that from an overall cost of capital, we think our cost of capital is somewhere in the 5 % to 7 % range. We also have a structure where we are very tax efficient, plus -- which makes us very competitive. And many of the other entrants in the market, when they're structured as private equity funds and are asking investors to give them capital, that's going to be -- and this is important -- capital that's going to be locked up for 3, 5, 7 years with no liquidity.  Those investors will not invest if the people are raising the money in a fund, are not promising teams mid and high teams return. Peoples don't give you money if you cannot deliver, things return, if there's no liquidity and if the money's locked up for some period of time.  As you know, one thing that we told repeatedly investors, is that for many of the really attractive, high-quality royalties in the proof products, to be able to complete a transaction and have the seller of the royalty that can be a Company, a university, a hospital, really be willing to sell the asset, you have to buy it at high single-digit, low double-digit returns, which we can very easily get to and still have very attractive returns.  Because when we lever that high single-digit, low double-digit return, we're now in the high teens, even 20s IRR level, very predictably, very stable, but we can do that because of our cost of capital.  Someone with a fund having promised investors teens returns, it's super difficult for them to be able to buy a royalty at high single-digit, low double-digit and still deliver attractive returns to their investors, given the -- what they promised as returns and given the lack of leverage -- low-cost leverage.  We have a lot of really strong competitive -- and also other things that are intangible, the net where we have of relationships, the team we have which has worked together very cohesively for more than a decade, and so on. I'll stop there and maybe Terry can add some comments about Avi.
Terry Coyne: So certainly, something that we're following at this point, it's just tough to say we haven't seen any data. I think, just to go back to the point I made earlier, Trikafta has been transformative for many patients with CF, so we think it sets a really high bar. We'll be interested to see the data that hopefully they disclose in the beginning, I guess, of 2022. But we think that Trikafta will continue to play a very important role in the treatment of CF over the long term.
George Grofik: Operator, we'll take the next question.
Operator: Thank you. Our next question comes from Greg Fraser with Truist Securities. You may proceed with your question.
Greg Fraser: Good morning, folks. Thanks for taking the question. I wanted to follow-up on the diversification question. Where would you say the bigger disconnect is between street thinking and your plan? Is it the growth potential of the current portfolio or your ability to significantly expand the portfolio over the next few years?
Pablo Legorreta: I think growth is definitely an area where I think investors and analysts have not appreciated the ability of Royalty Pharma to deliver consistent, predictable, high growth, which is very unique. In life sciences, there's really not many businesses that have this characteristic. We have growth that is attractive and has 3 very interesting attributes. 1. Is the high level of growth, the diversity of growth, again, very unique, so our growth is not reliant on 1 or 2 drugs, which is what you often see with biotech companies that are launching a product.  Yes, they will experience high growth, but it's all reliant on 1 or 2 products. And even big companies, we've seen situations where in PD-1, for example, there were expectations that one of the PD-1s was going to be much bigger than the other. That didn't pan out. And obviously it hurts the growth of the Company that had that drug.  And again, that played out over the last 5 -- 7 years, but really shows how even some of the big companies are reliant on 1, 2, 3, 4 drugs to drive the growth, and obviously also very reliant on few drugs to drive profitability because they have, obviously, lower margin. In our case, because our growth is derived from a very broad portfolio, very well-diversified portfolio, it's much more predictable.  And also, our bottom line is much more predictable for the same reason because of our 90 % margins. But then, the other thing that's very unique with Royalty Pharma is the duration of growth. We have a portfolio that has 15 years of winner average duration of when you weigh our revenues by  which is very, very unique.  Many companies -- big companies have winter average durations of 6, 8, 9, 10 years, but it's rare to see a duration that's as long as ours. So, there's no question that I think growth is an element that is not well understood, appreciated. And then the ability for us to deploy capital consistently and add -- continue to add blockbusters to our portfolio.  And in our roadshow, we had a few  that really showed how we have 22 blockbusters in our portfolio, which is 3 times as many as any of the Big Pharma. And 7 products that have revenues of $3 billion or more, which again is about 3 times the number of drugs that's held $3 billion or more of that the typical Big Pharma has.  And again, what's interesting is that because of our openness -- the openness of our business model, where we're not constrained by third-party classes or also sales force in 1 or 2 therapeutic classes or 5 therapeutic classes, classes, and clinical infrastructure, clinical groups and teams in a few therapeutic classes, we can really look at the entire life sciences landscape and deploy capital and add  budgets on a much faster rate than many of the big companies can develop them.  So, it's a very unique business. And I think one way to think about it is that we really have, if you think of Royalty Pharma, the entire life sciences, R&D &D infrastructure and landscape that is constantly developing new drugs for us to actually either find them, and create a data royalty or acquire Royalty that exists on a product that has already developed.  We're actually -- could also being developed, but we have the entire R&D landscape of the entire industry where we can actually deploy capital again. So that's very unique and I think investors have really not well understood that. And it's what drives the -- has driven the success of Royalty Pharma and the very strong growth over an extended period of time.
Greg Fraser: Great, thanks for the color.
Operator: Thank you. Our next question comes from Steve Scala with Cowen, you may proceed with your question.
Steve Scala: Thank you. I have a few questions all focused on your upside opportunity. First, how will Royalty Pharma benefit from the Avi Imbruvica patent decision and potential extension if it stands? And if you could provide any quantification of the benefit that would be helpful. Similarly, how do you think about Pfizer 's partnership with Biohaven for OUS rights to Nurtec as far as impact on your business?  Again, any high-level quantification would be helpful. And then lastly, with gantenerumab looking to have even bigger potential as time goes on, I'd like to get a few points clarified. First, are your rights to the asset global? And secondly, is the royalty the same weather the sales are in gantenerumab or gantenerumab shuttle? Thank you.
PabloLegorreta: Yes, I think Marshall is ideal to answer the last 2 questions, or even the first one. So go ahead, Marshall.
Marshall Urist: Yeah, Steve. Thanks for the question so I was trying to write them down as you were going through. So first one on the Imbruvica -- on the Imbruvica patent news. The first point there, just to level set for everyone is that we had previously expected our Imbruvica Royalty the to expire between 2027 and 2029. And then we recently got the news about the court decision that upheld some of Avi's Imbruvica patents.  Now Avi has publicly disclosed that they don't expect generic entry in the U.S. until March 30th, 2032. So, our position is that we are entitled to royalties on Imbruvica in the U.S. until 2032. So, you hard to quantify that necessarily at this point, but I think you can kind of look at your model in the forecast and think about what that might what that might mean for the model.  So, I hope that's helpful. I think your second question was on the Pfizer - Biohaven relationship. And our perspective on this is certainly driven by a long history of seeing products play out over years and years and really appreciating what the global opportunity for medicines can be, and often times that's even bigger than what's in the U.S.  But it certainly takes companies with very broad, deep infrastructure in multiple companies to get the drug out there to as many patients and countries as possible. And I think we can't think of a better partner for Biohaven to help make that happen than Pfizer. And so, we were very happy to see the news and I think as we think about the impact on our business, certainly our royalties are global on that.  And so, you can't help but enhance the value of our ex-U.S.-- of the ex-U.S. portion of the royalties on Nurtec and whatever else may come from the presentation -- from that -- from that collaboration. Then the third question was on gantenerumab. And so, I think they're -- the first question is just very simply, is our royalty on worldwide sales, and the answer to that, is yes.  And then on the shuttle, so on the shuttle, I -- we haven't gotten into specific details as to exactly how that works beyond to say that, yes, the Shuttle is royalty-bearing to Royalty Pharma. Still early sounds like Roche are -- sounds like Roche is moving it along, which is great and we'll look forward to further developments there.
Steve Scala: Thank you.
Operator: Thank you. Our next question comes from Geoff Meacham with Bank of America. You may proceed with your question.
Geoff Meacham: Hey, guys. Thanks so much for the question. I have 2, and mostly just on the strategy and the business model. For the first one, there are some technologies or therapeutic areas that have evolved rather quickly. COVID's example of this, I guess the question for maybe for Marshall is: How has your diligence process evolved to become a little bit nimbler and is there an increased focus on some of these fast-track opportunities in biopharma?  And the second one, maybe for Pablo just a follow-up to the competition. When you look at PT027, it's more of a formulation play than say a novel mechanism and as you look across all the high-impact opportunities in biopharma, many being earlier and higher risk; what are your thoughts of investments in healthcare that are outside of the therapeutic s realm? Thanks, guys.
Pablo Legorreta: Marshall, do you want to figure the first question?
Marshall Urist: Sure. I think they're 2 -- Hey, Jeff. Good morning and thanks for the question. I think there's 2 aspects to your question. The first is, how we are thinking about opportunities that can gather momentum quickly, like COVID has, either on the therapeutic side or on the vaccine side and so there is 2 aspects to that.  I think the first is our approach to those things is very consistent with how we've always looked at things in the past, which is, does this makes sense? Do we -- is this meaningful -- meaningful science for patients? And does it check that box?  And second, do we think there is a -- an attractive long-term opportunity that would be value enhancing to our portfolio, and I think we treat things, no matter the velocity of how quickly they develop, in the same way from that perspective.  The 2nd part of your -- the 2nd aspect for your question is a good 1, too, which is, how do we structure our team and our diligence approach to be able to handle those opportunities if they do come fast and it's not something that we can see coming miles away. And so that's a good question. And we have been thinking a lot about that.  And I think we are evolving to be able to move quickly by the internal resources that we've been adding like the strategy and analytics team that we've talked a lot about in the past. And then also just continuing to expand and deepen our external network that Pablo mentioned as well. So, I think we're in good stead whether or not they are slow developing new part of the therapeutics landscape or something that happens quickly.
Pablo Legorreta: Geoff, maybe just to add to the answer that Marshall provided. There's really no restriction as to what we can do. I mean, we've looked in the past for devices and all sorts of technologies that produce royalties not only therapeutics. And sometimes it could be not -- as you know, patents are issued on many things, not only as a composition-of-matter patent on a drug, but many other things, and they give rise to royalty.  We're very open-minded about anything that could result in a percentage of revenue, of Royalty. And have looked at so many different things over the year. But I think -- like an example of that is, like the collaboration with Edward MSCI, where at the end indexes are going to be created. And we've made great progress with MSCI on that and to start to launch some of the things in the very near term, in the next few months.  But at the end, that's going to generate revenue tied to assets under management investment in life sciences, which will grow for many decades. But anyway, the other comments I would make is that if there's anybody that can move quickly, very quickly. You know, to react to opportunities it's us, and we can do it because we have a team that is constantly talking to companies and just reacting very quickly to opportunities.  In many cases, we have models built up already where there are some products that is of interest. We have a model for solid tumors where recover every solid tumor and all of the drugs that are in the market today, drugs that are being developed, and we have a view on those drugs. But when opportunity comes to us, we can react very, very quickly.  But the other thing that is very, very unique and talking about things that are underappreciated by investors, is that if a Company -- think of a Company like Biogen that's in MS and Alzheimer's. Or think about a Company like  that was in hematology and inflammation.  If a Company like that -- once you get into a new therapeutic area, it can take them 5 to 10 years. They can make -- go and make an acquisition and get into a therapeutic area. But even that takes time, obviously, M&A is complicated, very competitive with few assets that are attractive for big companies and obviously there are issues now with antitrust that is making M&A for big companies difficult, and that's why we're so excited about M&A in mid-cap companies.  But leaving aside M&A, if a Company wants to diversify and getting into a new therapeutic area, they have to create -- they have to buy an asset, they have to create a clinical , they have to invest years in clinical trials, they have to then launch it. It can take 5 to10 years.  In our case, if they're interesting areas for us to invest in, we can -- so quickly, if there's a royalty that we're interested in on our approved product that is already generating cash flow, we can have discussions with the holder and potentially acquire it. If there's a product that's in development that we're interested in a new therapeutic area.  We can go into -- we can finance our product and create our Royalty and we end up having an investment in that area in a matter of month, week. Is it going to take a year because -- or more because we're following things all the time? Then at the right moment we decide to make a move and we can have an investment very quickly.  But the point is that, it allows us the openness of the business model and the lack of constraint, like therapeutic constraints, therapeutic biases, allows us to really make investments in the new areas that are exciting with great  much more than any Company.  That's what's so unique about this business model that it's so attractive as a way for investors really get exposure to this incredible innovation that's occurring in life sciences, and in many cases, in the most exciting new areas. We were not -- look at the investments we've made over the recent years and some of the new gene therapies. And it was easier for us and quick. But anyway, Chris maybe you want to add some additional comments to this, given your perspective of decades helping companies in life sciences.
Chris Hite: Sure. Thanks, Pablo, and thanks for the question, Geoff. I think Pablo covered a lot of that. I think there is -- the one thing that we really have started to really look at is the total addressable market and the cumulative R&D spend at the sector over the next decade is roughly over $2 trillion.  And we looked at that as just a huge opportunity to get involved and whether it's new technologies as you highlight new opportunities, synthetic royalties given how fractured the R&D environment is in the sector, the actual new royalty that will be created through that spend. We just look at this as a tremendous opportunity in a therapeutic space. But if there's other royalties that exist outside of that, we're not necessarily opposed to that either.
Geoff Meacham: Okay, great. Thanks, guys.
Operator: Our next question comes from HUMIRA bottling Evercore you may proceed with your new question.
Umer Raffat: Hi, guys. Thanks for taking my question. I have two if I may, perhaps first on M&A side. It looks like you've been fairly quiet since the MorphoSys deal announcement in June. And I wonder if we should perceive that as a sign of something bigger that's in the works, I'd be very curious. And then secondly, on the big catalyst on your pipeline heading into next year. Again, scenario MAB Phase three, assuming Phase III goes well, do you expect this to be a multi-billion-dollar product? Thank you very much.
Pablo Legorreta: Good to hear you, Omar. And interesting question about MorphoSys. I think an M&A in general -- I think what pulls investors is that there is -- and Chris just mentioned $2 trillion of investment in R&D in life sciences over the next decade. It's -- and it's going to be about $1 trillion over the next 5 years. The industry, when you look at how much it spends, it's about $300 billion per year, $200 billion by Biotech and Large Pharma, Big Pharma globally.  And another $100 billion by government medics -- I'm sorry, governments, NIH and foundations. And so, it's an incredible number. When you look at many, many other industries around the planet, they invest in the tens of billions of dollars per year in R&D. One of the few industries that invest at a scale up hundreds of billions of dollars in R&D per year is Biosciences, and we're at the middle of this.  Royalty Pharma is becoming the partner of choice to help companies fund part of that investment. So, it's something to be a huge opportunity, but that -- the more conventional deals that we're doing every quarter, every year, probably will have us invest more than $1.5 billion, probably more than $2 billion per year. And then the ones that are going to be difficult to predict is M&A transaction.  And are we going to have 1 or 2 per year or 1 or 2 every 2 or 3 years. It's hard to tell. But the reality is that one interesting new thing that we're realizing could become a really important driver of opportunity for us is mid-cap M&A, like what happened with MorphoSys. And that is going to add to the more conventional deals that we're able to do every year.  And I think there are some big things out there. Now for those things to really happen the spark coupler line there has to be a deal where two companies want to transact and we are then able to potentially partner with one of them to help them.  They're difficult transactions to be honest, but it's things where we have experience and we've been successful, and I think it's something that I spend, personally, a lot of time looking at, because that's where I think we will have, also, very, very attractive opportunities in front of us. And I guess there was -- was there another question? Sorry, I missed the other questions.
Operator: Maybe on Gantenerumab.
Umer Raffat: And my question was around your expectation for Gantenerumab commercial opportunity if the trial holds.
Pablo Legorreta: Yeah Marshall?
Marshall Urist: Absolutely. Hey, Umer. Good morning. On Gantenerumab, like we mentioned in the script, we're really excited now to have this as part of the portfolio post the MorphoSys deal, and are looking forward to the data next year. And to answer your question, yes. Our thesis has been that an anti-amyloid product in this class that has a very consistent dataset and shows clear efficacy and safety and is supported by a big global Company and has a really attractive  dosing profile like Gantenerumab.  And it checks all those boxes, certainly had the potential to be a multi-billion-dollar products. Like we've mentioned in the past, we always look at it on a scenario, whenever we bring anything into the portfolio. But certainly, this is when that can support multi-blockbuster potential.
Umer Raffat: Thank you.
George Grofik: Operator, we have time for one last question.
Operator: Your last question comes from Matthew Harrison with Morgan Stanley. You may proceed with your question.
Charlie: Hi, thanks for taking the question. This is Charlie  for Matthew. Just 2, I guess, follow up question. I think one, can you just talk about maybe just ultimately dynamics a little bit at a high level given how biologist launch and how that could impact your view in terms of the royalties there. And then second, maybe if you can discuss a little bit about the cystic fibrosis arbitration procedure if it gets to that step. Thank you.
Pablo Legorreta: Jim, would you mind picking the question on gantenerumab then maybe it's Terry, can also talk about potential arbitration with respect to CF.
Jim Reddoch: Sure. I am just -- yeah, sorry, I had to recall the question. I mean, Biogen has had a slower than expected rollout. Maybe not that big of a surprise because it has had its reimbursement issues in its roll out, and came to the market with efficacy package that was viewed by practitioners and payers as being sub-optimal.  We're hopeful that the product that we're invested in Gantenerumab is going to come to market with a differentiated profile and one that shows compelling efficacy and some real kind of improvements over what that product is showing.  So, I wouldn't view what Biogen 's experience has been as what is possible with a quality product in Alzheimer's, which still a huge unmet need is. And I think there is the possibility that an amyloid acting antibody in it really could be valuable to patients, is developed correctly and has good data.
Pablo Legorreta: Maybe I'll ask something -- I'll ask this very quickly. There's a huge unmet medical need as you know. Really 1 of the biggest in the world in the world. And the patients need a drug that works and a drug that has the characteristics of Gantenerumab.  So, we're very excited about having that in our portfolio because it could become best-in-class and it could become one of the biggest drugs if the profile holds, it could be one of the biggest drugs in healthcare. So, it's -- it's really exciting to have that in our portfolio. But go ahead, Marshall. Sorry.
Terry Coyne: Yeah. This is Terry. I'm going to address the CF question. There is a dispute resolution mechanism in the contract, but at this point it's really not appropriate for us to discuss any legal strategy.
Charlie: Thank you.
Operator: Thank you. And I'm not showing any further questions at this time. I would now like to turn the call back over to Pablo for any further remarks.
Pablo Legorreta: Thank you, Operator. And thank you to everyone on the call for your continued interest in Royalty Pharma. My team and I look forward to continuing to share our progress with you. If you have any follow-up questions, please feel free to reach out to George and our Investor Relations, team. Thank you very much. Goodbye.
Operator: Thank you. This concludes today's conference call. Thank you for participating. You may now disconnect."
